Bathi sadurunge bunga, pajak, lan amortisasi: Immutep (IMMP)

Logo grafis immutep.com (IMMP)

Operating profit before depreciation on GURU.Markets reflects a financial trend where the 0.00 level serves as a critical mark. Immutep Limited (IMMP) develops advanced LAG-3 protein methods to activate immunity against tumors. The company is currently scaling its portfolio of innovative combinations within clinical trials. In the future, the licensing of molecules will ensure low production costs and colossal margin growth.

IMMP Bathi operasional EBITDA Immutep (23.11.2025 - 10.11.2026)
Barang unggulan Immutep Limited ADR

Long-term risk control requires an analysis of cash flow stability, which allows for an assessment of the business's actual viability regardless of accounting accruals. By relying on operating profit dynamics, an investor can see the daily cash balance after deducting operating expenses, which for Immutep Limited (IMMP) is sustained through strategic alliances in the LAG-3 field, confirming the fundamental value of its developments.